OSCOR acquired by INTEGER
Context
Integer Holdings has successfully finalized the acquisition of Oscor, Inc., a strategic move designed to significantly broaden the group’s cardiovascular and neurostimulation product portfolios. This transaction integrates a robust range of proprietary products, including steerable sheaths and cardiac leads, into the acquirer’s existing medical device outsource framework. The strategic rationale for the move centers on the acquisition of specialized technical capabilities and a vast intellectual property portfolio that deepens relationships with existing Tier 1 customers while providing access to emerging growth companies. By incorporating the target’s established brand and its research and development expertise, the organization bolsters its "concept-to-commercialization" value proposition. A key component of the integration is the addition of the target’s manufacturing presence in the Dominican Republic, which provides high-efficiency, low-cost production capacity to support the group’s global expansion. This partnership reinforces the group’s standing as a primary technical enabler for the cardiac rhythm management and neuromodulation industries, ensuring the strategic depth required to exceed market growth rates in fast-growing clinical segments like structural heart and electrophysiology.
OSCOR, which reported an EBITDA margin of LOGIN in 2020, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Healthcare & Pharma market trends
Target
Oscor is a specialized medical technology organization dedicated to the design, development, and manufacturing of highly engineered implantable devices and venous access systems. The entity’s business model is centered on a "concept-to-commercialization" framework, providing a comprehensive line of finished introducer systems, guiding sheaths, and proprietary lead wire technologies. Its value proposition lies in its deep technical expertise in cardiac pacing, electrophysiology, and neurostimulation, serving both established medical device giants and emerging growth companies. Strategically, the firm focuses on high-growth clinical markets such as structural heart and peripheral vascular interventions. By maintaining vertically integrated operations—including research and development and industrialized manufacturing—the organization ensures technical durability and precision in mission-critical components. The entity facilitates the rapid deployment of complex medical solutions through its extensive intellectual property portfolio and specialized manufacturing footprint.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (USD)
Similar deals in Healthcare & Pharma
| Date | Acquirer | Target | Country | Sector | Deal Context |
|---|---|---|---|---|---|
| 01/2022 | ARDIAN | BIOFARMA GROUP | ITALY | Life Sciences | Ardian acquired a majority stake in Biofarma Group from White Bridge Investments. Ardian's entry is designed to transform the European leader into a global champion, specifically targeting expansion into the US and APAC markets while maintaining its technological lead in the high-margin probiotic segment |
| 01/2022 | PERMIRA | BIO PRODUCTS LABORATORY (BPL) | UNITED KINGDOM | Life Sciences | Permira acquired BPL from its sole shareholder, Tiancheng International Investment (TII), which had owned the business since 2016. The acquisition was part of a larger strategic plan to merge BPL's robust US collection network and specialized rare disease portfolio with Kedrion |
| 12/2021 | WINNCARE | PHARMAOUEST INDUSTRIES | FRANCE | Life Sciences | This transaction marks the first major structural acquisition for Winncare following the entry of Siparex ETI as its majority shareholder earlier in 2021. By acquiring 100% of Pharmaouest Industries, Winncare has significantly strengthened its industrial capabilities and product portfolio in the high-stakes segment of pressure ulcer prevention |
| 12/2021 | THE CARLYLE GROUP / GTCR | RESONETICS | UNITED STATES | Life Sciences | The strategic investment in Resonetics by Carlyle signifies a major territorial and technical advancement for the organization, building upon the momentum of eight successful add-on acquisitions. The strategic rationale for this transaction centers on a "platform-acceleration" maneuver, merging the target's industry-leading technical operational depth in micro-manufacturing with the new sponsor’s extensive global network and expertise in healthcare digitalization |
| 12/2021 | PLANMECA GROUP | KAVO DENTAL | GERMANY | Life Sciences | Planmeca has successfully finalized the acquisition of the treatment unit and instrument business from a major diversified global medical manufacturer. This strategic transaction represents a significant consolidation of the global dental equipment market, bringing together two of the most technically advanced portfolios in the industry |
| 11/2021 | COLOPLAST | ATOS MEDICAL | SWEDEN | Life Sciences | Coloplast has reached an agreement to acquire Atos Medical from the private equity firm PAI Partners. his transaction marks a major strategic exit for PAI Partners, which acquired the company in 2016. During PAI’s five-year ownership, Atos Medical more than doubled in size, transforming from a laryngectomy specialist into a diversified ENT leader with a significant foothold in the tracheostomy market |
| 09/2021 | PERRIGO COMPANY | HRA PHARMA | FRANCE | Life Sciences | The acquisition of HRA Pharma by Perrigo signifies the "crowning achievement" of the acquirer’s structural transformation into a pure-play consumer self-care leader. The strategic rationale for this transaction centers on a "portfolio-premium" maneuver, merging the target’s high-growth, margin-accretive branded assets with the acquirer’s massive expert direct go-to-market platform |
| 07/2021 | MONTAGU PRIVATE EQUITY | INTECH MEDICAL | FRANCE | Life Sciences | Intech Medical, a global leader in the manufacturing of orthopedic surgical instruments and implants, has entered into an agreement to be acquired by Montagu Private Equity. The transaction marks the exit of Eurazeo (specifically its mid-cap subsidiary) and Andera Partners, who have held a majority stake in the French group since 2017 |
| 07/2021 | PARTNERS GROUP | PHARMATHEN | GREECE | Life Sciences | Partners Group acquired 100% of Pharmathen from BC Partners, which had acquired the company in 2015. During its ownership, BC Partners invested over €250 million in R&D and new FDA-approved production facilities, nearly doubled the employee headcount, and repositioned Pharmathen from a traditional European generics manufacturer into a technology-driven global leader in complex drug delivery |
| 07/2021 | ORKLA | NUTRAQ | Norway | Life Sciences | Orkla completed its acquisition of NutraQ to strategically enhance its presence in high-growth market segments, specifically the health category and the direct-to-consumer (D2C) channel. The transaction provides Orkla with a new, subscription-based business model, diversifying its traditional go-to-market strategies and offering exciting growth opportunities |
REFERENCES
Valuation range: EV 100M - 350M USD
Revenue range: 50M - 100M USD
Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of OSCOR by INTEGER are reserved for mynth community members. Register for free to unlock full data.
Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).